Due to the elevated expression of CD39 in ovarian cancer and the tumor-targeting capability of CAR-T therapy, the combination of CAR-T cells with an anti-CD39 antibody may yield an effective response in patients with ovarian cancer. Here, ENTPD1 is linked to ovarian carcinoma.